Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase II Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

0
814
Medicus Pharma, Ltd. announced a positively trending interim analysis for SKNJCT-003 Phase II clinical study to non-invasively treat basal cell carcinoma of the skin.
[Medicus Pharma, Ltd.]
Press Release